Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 674,978 | 666,823 | 541,533 | 429,647 | 421,026 |
| Cost of Goods | 184,669 | 199,295 | 140,255 | 117,328 | 106,712 |
| Gross Profit | 490,309 | 467,528 | 401,278 | 312,319 | 314,314 |
| Operating Expenses | 403,303 | 407,799 | 311,609 | 266,297 | 304,546 |
| Operating Income | 87,675 | 60,024 | 89,924 | 46,350 | 10,480 |
| Interest Expense | 20,306 | 39,976 | 31,750 | 25,671 | 23,628 |
| Other Income | -5,668 | -6,746 | -1,770 | -590 | 2,400 |
| Pre-tax Income | 61,701 | 13,302 | 56,404 | 20,089 | -10,748 |
| Income Tax | 19,746 | -2,607 | 14,424 | -125,434 | 268 |
| Net Income Continuous | 41,955 | 15,909 | 41,980 | 145,523 | -11,016 |
| Net Income | $41,955 | $15,909 | $41,980 | $145,523 | $-11,016 |
| EPS Basic Total Ops | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 |
| EPS Basic Continuous Ops | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 |
| EPS Diluted Total Ops | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 |
| EPS Diluted Continuous Ops | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 |
| EPS Diluted Before Non-Recurring Items | 2.09 | 1.84 | 2.26 | 1.30 | 0.86 |
| EBITDA(a) | $166,997 | $158,732 | $144,378 | $86,668 | $45,509 |